Everence Capital Management Inc Uni Qure N.V. Transaction History

Everence Capital Management Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 04, 2023	BUY	$18.7 - $23.07 $191,862 - $236,698	10,260 New	10,260 $207,000
Q2 2022 Jul 26, 2022	SELL	$13.15 - $20.45 $168,057 - $261,351	-12,780 Closed	0 $0
Q1 2022 Apr 11, 2022	BUY	$14.54 - $21.5 $185,821 - $274,770	12,780 New	12,780 $231,000
Q4 2021 Jan 28, 2022	SELL	$20.24 - $36.01 $541,824 - $963,987	-26,770 Closed	0 $0
Q3 2021 Oct 21, 2021	BUY	$26.01 - $38.22 $696,287 - $1.02 Million	26,770 New	26,770 $857,000

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Everence Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Everence Capital Management Inc with notifications on news.